Blueprint Medicines/BPMC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Blueprint Medicines

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Ticker

BPMC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Albers

Employees

645

Headquarters

Cambridge, United States

BPMC Metrics

BasicAdvanced
$6.6B
Market cap
-
P/E ratio
-$4.82
EPS
0.70
Beta
-
Dividend rate
$6.6B
0.69921
$111.02
$43.89
683K
3.759
3.609
67.336
77.05
-23.37%
-25.53%
-79.53%
-30.68%
23.422
21.267
21.275
37.94%
50.35%
-32.02%

What the Analysts think about BPMC

Analyst Ratings

Majority rating from 18 analysts.
Buy

BPMC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
92.71% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$96M
33.66%
Net income
$89M
-180.34%
Profit margin
92.71%
-160.11%

BPMC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.59%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.19
-$2.20
-$1.82
-$1.32
-
Expected
-$2.54
-$2.37
-$2.04
-$1.66
-$1.29
Surprise
-13.77%
-7.06%
-10.78%
-20.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Blueprint Medicines stock?

Blueprint Medicines (BPMC) has a market cap of $6.6B as of June 18, 2024.

What is the P/E ratio for Blueprint Medicines stock?

The price to earnings (P/E) ratio for Blueprint Medicines (BPMC) stock is 0 as of June 18, 2024.

Does Blueprint Medicines stock pay dividends?

No, Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next Blueprint Medicines dividend payment date?

Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders.

What is the beta indicator for Blueprint Medicines?

Blueprint Medicines (BPMC) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Blueprint Medicines stock price target?

The target price for Blueprint Medicines (BPMC) stock is $119.41, which is NaN% below the current price of $. This is an average based on projections from 17 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Blueprint Medicines stock

Buy or sell Blueprint Medicines stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing